Literature DB >> 21415024

Assessment of a lupus nephritis cohort over a 30-year period.

Sara C Croca1, Teresa Rodrigues, David A Isenberg.   

Abstract

OBJECTIVE: LN is a common and potentially severe complication of SLE. Our aim was to characterize a LN cohort followed at a single centre for 30 years and assess its evolution over time.
METHODS: Between 1975 and 2005, 156 LN patients were followed up at University College Hospital London. We divided them into three groups depending on the date of recognition of renal involvement (1975-85, 1986-95 and 1996-2005) and compared them in terms of clinical, demographic and serological characteristics and disease outcome.
RESULTS: Clinical characteristics were comparable between groups; however, the proportion of Afro-caribbean (AC) patients and the prevalence of anti-ENA antibodies rose significantly over time. The 5-year mortality rate decreased by 60% between the first and second decades, remaining stable over the third decade. The 5-year end-stage renal disease (ESRD) rate remained constant. An increasing number of renal transplants (RTx) was performed with encouraging results. AC origin was associated with a poorer overall prognosis.
CONCLUSION: LN, a common complication of SLE, is associated with increased mortality and morbidity, particularly among AC patients. Despite encouraging results for RTx, once ESRD is established the prognosis is relatively poor and no improvement in preventing its development was achieved. Moreover, although a significant decrease in mortality was observed, it has remained stable for 10 years. These results suggest that we have maximized the benefits of conventional therapies and if further improvement is to be achieved, novel drug regimens must be developed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415024     DOI: 10.1093/rheumatology/ker101

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  37 in total

Review 1.  A model for lupus brain disease.

Authors:  Betty Diamond; Bruce T Volpe
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

2.  Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality.

Authors:  Anna Broder; Saakshi Khattri; Ruchika Patel; Chaim Putterman
Journal:  J Rheumatol       Date:  2011-09-01       Impact factor: 4.666

3.  Beta-adducin and sodium-calcium exchanger 1 gene variants are associated with systemic lupus erythematosus and lupus nephritis.

Authors:  Giuseppe A Ramirez; Chiara Lanzani; Enrica P Bozzolo; Laura Zagato; Lorena Citterio; Nunzia Casamassima; Valentina Canti; Maria Grazia Sabbadini; Patrizia Rovere-Querini; Paolo Manunta; Angelo A Manfredi
Journal:  Rheumatol Int       Date:  2015-06-05       Impact factor: 2.631

4.  The first year results of mizoribine/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis.

Authors:  Hidetoshi Kagawa; Tsutomu Hiromasa; Ryutaro Yamanaka; Reika Hayashi; Yoko Tsunashima; Tatsuyuki Inoue; Ken-Ei Sada
Journal:  Clin Exp Nephrol       Date:  2018-06-09       Impact factor: 2.801

5.  Lupus nephritis: Implications of the new ACR lupus nephritis guidelines.

Authors:  Hans-Joachim Anders; Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2012-07-24       Impact factor: 28.314

6.  Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3.

Authors:  Seon-Yeong Lee; Su-Jin Moon; Eun-Kyung Kim; Hyeon-Beom Seo; Eun-Ji Yang; Hye-Jin Son; Jae-Kyung Kim; Jun-Ki Min; Sung-Hwan Park; Mi-La Cho
Journal:  J Immunol       Date:  2017-02-27       Impact factor: 5.422

Review 7.  Lupus Nephritis: A Different Disease in European Patients?

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Kidney Dis (Basel)       Date:  2015-08-28

Review 8.  CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside?

Authors:  L Schiffer; K Worthmann; H Haller; M Schiffer
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

Review 9.  Genetics of human lupus nephritis.

Authors:  Taro Iwamoto; Timothy B Niewold
Journal:  Clin Immunol       Date:  2016-09-28       Impact factor: 3.969

Review 10.  Recent clinical trials in lupus nephritis.

Authors:  Michael M Ward
Journal:  Rheum Dis Clin North Am       Date:  2014-06-07       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.